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Abstract. Enhanced motility of cancer cells by remodelling
of the actin cytoskeleton is crucial in the process of cancer
cell invasion and metastasis. Although several studies propose
a tumor suppressor role for the actin bundling protein
myopodin, it was also shown previously that overexpression
of mouse myopodin promotes invasion in vitro. In the present
study, the role of myopodin in human cancer cell motility
and invasion was explored using RNA interference with
siRNA duplexes designed to down-regulate all human
myopodin isoforms currently identified. We show that down-
regulation of myopodin expression in human cancer cells
significantly reduces the invasive properties of these cells
both in collagen type I and in Matrigel®. Furthermore, the
motile characteristics of cancer cells are also curbed by
reduced myopodin expression whereas cell-cell contacts are
reinforced. These results point to a role for myopodin as
tumor activator. While these findings are at variance with the
suggested tumor suppressor role for myopodin, we hypo-
thesize that the subcellular localization of the protein is
involved in its suppressor or activator function in tumori-
genesis.
Introduction
Metastasis, a complex process characterized by the spread
of tumor cells from the primary tumor to distant sites and
organs, is the major cause of death in cancer patients. Although
the molecular and cellular mechanism of cancer invasion and
metastasis is not fully understood, it is clear that the acquisition
of enhanced motility by cancer cells is a major requirement
for these events (1). During the process of cell migration,
the organization of the actin cytoskeleton is dynamically
remodelled through the concerted action of different classes
of actin binding proteins. Many of these actin binding proteins
display altered expression levels in malignant cells. For
example, expression of the actin capping protein CapG is
upregulated in several cancer types including glioblastomas
(2), ocular melanomas (3), pancreatic ductal adenocarcinomas
(4) and oral squamous cell carcinomas (5). Decreased
expression of the actin monomer sequestering protein profilin
has been observed in breast cancer (6), pancreatic cancer (7)
and hepatocarcinomas (8). Furthermore, the group of
Condeelis used an in vivo invasion assay to collect the
invasive cell population from primary mammary tumors in
intact animals using chemotaxis of cancer cells to growth
factors. Gene expression profiling of these invasive cells
compared to the tumor cells that remained behind in the
primary tumor revealed that many proteins involved in
regulation of the cytoskeleton, including a gelsolin-like actin
filament capping protein, cofilin, vinculin and zyxin, are
upregulated in the invasive cells indicating the enhanced
migratory behaviour of these cells (9,10). Although it is clear
that several aspects of tumorigenesis, including migration and
invasion of tumor cells, are related to altered expression of
the actin binding proteins, the underlying mechanism
remains to be elucidated.
The present study focuses on myopodin, the second
member of the synaptopodin family. Myopodin is an actin
bundling protein that shuttles between the nucleus and the
cytoplasm in a differentiation-dependent manner in muscle
cells (11). A single nuclear localization sequence mediates
nuclear entry of the protein (12). We have recently shown
that mammalian cells, including cancer cells, express three
myopodin transcripts that differ at their carboxy-terminus
(13). Furthermore, expression of myopodin has also been
observed in prostate, small and large intestine (14), normal
urothelium and tumors of the bladder (15). A number of
studies propose that myopodin contains tumor suppressor
activity in urothelial carcinoma and prostate cancer (14-16).
However, we have previously shown that expression of
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mouse myopodin in non-invading cells promotes invasion of
these cells into a collagen type I matrix (17). Such apparent
controversial results have also been observed for other actin
binding proteins like gelsolin (4,18,19), CapG (2,5,20), cofilin
(21-24) and ·-actinin 4 (25-27) making it difficult to classify
actin binding proteins either as a tumor activator or as a
tumor suppressor.
In this study, RNA interference was used to knock-down
myopodin expression in human cancer cells. Subsequently,
several assays were performed to determine the effect of
myopodin down-regulation on the invasive and motile
behaviour of these cancer cells. Our results show that
decreased expression of myopodin inhibits motility and
invasion of the cells indicating a role for myopodin in the
metastasis cascade of cancer cells.
Materials and methods
Cell culture. PC-3 and RT4 cells were maintained at 37˚C in
a humidified 10% CO2 incubator and grown in RPMI-1640
(Gibco-BRL Life Technologies, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum, 100 μg/ml
streptomycin and 100 IU/ml penicillin.
Transient gene knock down via specific siRNAs. Annealed
siRNA duplexes specific for human myopodin and RhoA
(28) were obtained from Eurogentec (Seraing, Belgium).
Both myopodin siRNAs are targeted to the complementary
region of all three human myopodin isoforms.
The following siRNA sequences were used for myopodin: 
sense siRNA sequence 1: 5'-GCACCUCCUUCUCUGGUA
UdTdT-3'; antisense siRNA sequence 1: 5'-AUACCAGAGA
AGGAGGUGCdTdT-3'; sense siRNA sequence 2: 5'-GGAG
GAUACAUGUGAAGUAdTdT-3'; antisense siRNA sequence
2: 5'-UACUUCACAUGUAUCCUCCdTdT-3'. The Rho
siRNA sequences are: sense siRNA sequence: 5'-GACAUGC
UUGCUCAUAGUCdTdT-3'; antisense siRNA sequence:
5'-GACUAUGAGCAAGCAUGUCdTdT-3'.
PC-3, PC-3-Myo cells [lentiviral transduced cells that
overexpress human myopodin isoform 1 (13)] and RT4 cells
were transfected with small interfering RNA (siRNA) duplexes
(50 nM) at 80% confluency using lipofectamine 2000
(Invitrogen Life Technologies, Merelbeke, Belgium) according
to the manufacturer's instructions.
A negative control siRNA duplex obtained from
Eurogentec, consisting of a unique sequence that does not
match with any other sequence in the human genome, was
used under similar conditions. Seventy-two hours following
transfection, the cells were harvested.
Invasion assays. Invasion into collagen type I was performed
as described previously (29). Gels were prepared in a 6-well
plate from a collagen type I solution (Upstate Biotechnology,
Lake Placid, NY) and incubated for at least 1 h at 37˚C to
allow gelification. Cells (1x105) were incubated on top of
the gels for 24 h at 37˚C. Cells inside the gel were scored
with a phase contrast microscope controlled by a computer
program. Invasive and superficial cells were counted in 12
fields of 0.157 mm2. Trypan blue staining was performed to
check the viability of the cells. The invasion index is the
percentage of cells invading the gel over the total number of
cells counted. Experiments were performed in triplicate.
Mean values and standard deviations were calculated.
Cell invasiveness was also determined by the ability of
cells to transmigrate through a basement membrane (ECM)
in Matrigel (QCM™ 24-well Invasion assay, Chemicon®
International, Temecula, CA). This was performed according
to the manufacturer's protocol. Briefly, cells were placed in
Matrigel inserts at 1x106 cells/ml in serum-free medium and
10% fetal bovine serum was used in the lower chamber as a
chemoattractant. Cells were allowed to migrate for 24 h at
37˚C. Cells at the bottom of the insert membrane were
dissociated from the membrane by incubation with cell
detachment buffer. These cells were subsequently lysed and
CyQuant GR® dye was added (Molecular Probes, Eugene,
OR, USA). Fluorescence was measured with a 480/520 filter
set. Data are expressed as relative fluorescence units (RFU).
Assays were performed in triplicate.
Fast aggregation assay. Cell-cell adhesion was numerically
evaluated in an aggregation assay as described previously
(30). Briefly, single cell suspensions were prepared with an
E-cadherin-saving procedure including detachment by
collagenase A (Boehringer Mannheim) treatment followed
by trypsin, both in the presence of 0.04 mM Ca2+. The cells
were allowed to aggregate on a Gyrotory shaker (New
Brunswick Scientific, New Brunswick, NJ) at 80 rounds per
minute for 30 min in aggregation buffer containing 1.25 mM
Ca2+, 0.1 mg DNase/ml, 10 mM HEPES and 0.1% BSA and
equilibrated at physiological pH and osmolarity. Cell
aggregation was measured with an LS particle size analyser
(LS200, Coulter Electronics) after 0 and 30 min of aggregation.
The relative volume as a function of particle size was used as
an index of aggregation. Kolmogorov-Smirnov statistics was
used to analyze the differences between the cumulative
distribution curves obtained in the fast aggregation assay.
Wound healing assays. Equal numbers of PC-3 cells (900000)
were seeded into 6-well cell culture plates. Eighteen hours
after seeding, cells were transfected with either Myopodin
siRNAs or with the siRNA negative control provided by
Eurogentec. Seventy-two hours after transfection a wound
was made by scratching a line in a confluent monolayer. The
debris was removed by washing the cells with serum-free
medium. Migration of cells into the wound was then
observed at different time-points. To this end, the width of
the wound (in μm) was measured at different points across
the wound (3 points in each wound, and three wounds for
each well of the culture plate) at time-point 0 and this
measurement was repeated at hourly intervals at the same
locations. Cells were followed for 8 h. Afterwards, the distance
that the cells migrated (in μm) was calculated for each point
of measurement and each time-point by reducing the width of
the wound at time-point 0 with the width of the wound at that
time-point. Finally, for each time-point, the average of the
distance migrated at the different points of measurement was
taken and plotted. Data are means ± SE of three independent
experiments.
Lentiviral transduction (generation of PC-3-Myo cells). V5-
tagged human myopodin isoform 1 was cloned into the
pLVTHM vector (kindly provided by Dr D. Trono, Lausanne,
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Switzerland) by excision of GFP cDNA from pLVTHM
using the restriction enzymes PmeI and SpeI. Recombinant
lentiviruses were produced by triple transfection of HEK293T
cells. HEK293T cells (8x105) were transfected using calcium
phosphate precipitation with 3 μg of the pLVTHM-myopodin
lentiviral vector, 3 μg of pMD2G-VSVG packaging plasmid
and 1.5 μg of the psPAX2 envelope plasmid. 24 h before
transduction, 105 PC3 cells were seeded onto 24-well tissue
culture dishes. The medium was replaced with 800 μl of the
lentivirus-containing medium to which 5 μg/ml polybrene
was added. Cells were then centrifuged for 90 min at 700 rpm
and 32˚C. Subsequently, 800 μl RPMI with 10% FBS was
added and the cells were maintained at 37˚C in 5% CO2. The
next day, transduction was repeated.
Western blotting. Cells were disrupted in ice-cold lysis buffer
(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton-X100,
1 mM PMSF, and a protease inhibitor cocktail mix). Insoluble
material was removed by centrifugation (20000 x g for 10 min
at 4˚C). Protein concentrations were determined by the method
of Bradford (31) using bovine serum albumin as a standard.
Western blotting was performed as described (32) with anti-V5
antibody (Invitrogen). Proteins were visualized by enhanced
chemiluminescence detection (ECL, Amersham Pharmacia
Biotech, Buckinghamshire, UK).
Results
Down-regulation of myopodin expression counteracts tumor
cell invasion. It was previously demonstrated that over-
expression of mouse myopodin in human endothelial kidney
cells (HEK293T) or in mouse C2C12 myoblast cells induces
invasion of these cells into a collagen type I matrix (17). In the
current study, we investigated whether reduced expression of
myopodin in cancer cells could also modulate the invasive
properties of these cells. To this end, we designed two
myopodin siRNA duplexes to down-regulate myopodin
expression in human cancer cells. As no reliable myopodin
antibodies are available to detect endogenous myopodin on
Western blotting (13) we devised an alternative way to show
the reliability of the myopodin siRNA duplexes. PC-3 cells
were transduced with the lentiviral pLVTHM vector encoding
V5-tagged human myopodin isoform 1 (13) to create a
stable cell line that overexpresses V5-tagged myopodin.
Subsequently, this cell line, called PC-3-Myo, was transiently
transfected with one of the myopodin siRNA duplexes.
Western blot analysis using a monoclonal anti-V5 antibody
revealed that both duplexes reduced the expression of V5-
tagged myopodin indicating that the two myopodin siRNA
duplexes can be used to efficiently knock-down endogenous
myopodin expression (Fig. 1).
Several assays were used to assess the effect of myopodin
knock down on cell motility and invasion. Initially, we studied
the effect of myopodin down-regulation on the invasive
capacity of cancer cells into a collagen type I matrix. The
invasive bladder cancer cell line RT4 was transiently trans-
fected with a myopodin siRNA duplex and these cells were
subsequently seeded on top of a collagen type I layer. We
could observe dramatically reduced invasive properties of
these cancer cells in a collagen type I matrix (for both siRNA
duplexes) in comparison to the negative control siRNA
duplex (Fig. 2).
Collagen type I represents only one component of the
interstitial stroma. However, a critical event in the metastatic
cascade is the invasion of cancer cells through the basement
membrane. A more suited model for invasion of cells
through this basement membrane is a matrigel invasion assay
(33). PC-3 cells transfected with the myopodin siRNA
duplexes 1 or 2 showed a substantially reduced invasion
through Matrigel compared to the negative control siRNA
treated cells (Fig. 3). These results are in line with the
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Figure 1. Knock down of myopodin expression in PC-3-Myo cells by
myopodin siRNA duplexes 1 or 2. A PC-3 cell line stably overexpressing
V5-tagged human myopodin isoform 1 (PC-3-Myo) was transiently trans-
fected with the myopodin siRNA duplexes 1 or 2. Western blotting on PC-3
cell extracts with anti-V5 antibody shows that both duplexes efficiently reduce
myopodin expression. Protein markers (in kDa) are shown on the left. The
expression of actin is shown as a control for equal loading. Lane 1, negative
control siRNA; lane 2, myopodin siRNA 1; lane 3, myopodin siRNA 2.
Figure 2. Myopodin RNA interference in RT4 cells inhibits collagen type I
invasion. RT4 cells were transiently transfected with myopodin siRNA
duplexes 1, 2 or a negative control duplex. Both myopodin siRNA 1 and 2
reduce the invasion of RT4 cells in collagen type I. Data are means ± standard
deviation of three independent experiments.
Figure 3. Down-regulation of myopodin expression reduces invasion of PC-3
cells through Matrigel®. Myopodin siRNA 1 and 2 inhibit invasion of PC-3
cells into Matrigel. RhoA siRNA was used as a positive control. RFU,
relative fluorescence units are shown in the y-axis. Data are means ± standard
deviation of three independent experiments.
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collagen type I invasion assay. PC-3 cells transfected with a
RhoA siRNA duplex were used as a positive control. Over-
expression of this small GTPase has been observed in several
human cancers (34,35) and down-regulation of RhoA using
siRNA in MDA-MB231 breast cancer cells inhibited cell
invasion effectively (28). The level of decreased invasion
induced by myopodin RNA interference was of the same
order to that observed after RhoA down-regulation.
Down-regulation of myopodin expression affects cell
migration and cell-cell contact formation. Both in vitro
invasion assays indicate that the expression levels of human
myopodin influence the invasive capacity of cancer cells but
the underlying mechanism is not clear. Different cellular
activities are involved in the process of invasion including
loss of cell-cell adhesion, changes in the cell-matrix
interaction, activation of extracellular proteases and
increased motility. An important factor in the process of cell
movement is the dynamic remodelling of the actin cyto-
skeleton, regulated by actin binding proteins. As myopodin is
an actin bundling protein, we addressed the question whether
myopodin has a direct effect on the motility of cancer cells.
To this end, we investigated the effect of myopodin down-
regulation on cell motility by using a wound healing assay. In
this assay, a wound is made in a confluent layer of cells and
the time required for wound closure is measured. We
observed that PC-3 cells treated with the myopodin siRNA
duplexes 1 or 2 showed a significant decrease in wound
closure efficiency in comparison to control siRNA treated
cells within a time span of 8 h (Fig. 4).
Another important characteristic of invading cancer cells
is loss of cell-cell contacts. Because the key molecule in cell-
cell adhesion, E-cadherin, is connected to the actin cyto-
skeleton, we examined the effect of myopodin down-
regulation on the E-cadherin-dependent formation of cell-cell
contacts and thus on the formation of cell aggregates in a fast
cell aggregation assay (36). A single cell suspension of PC-3
cells treated with the negative control siRNA duplex did not
aggregate into large particles. The aggregates that were
formed had a particle size of 10-100 μm after 30 min of
aggregation. After transient transfection of the cells with
myopodin siRNA duplexes 1 or 2, the PC-3 cells were able
to form aggregates with a larger particle diameter than the
particle diameter of the negative control siRNA treated PC-3
cells (Fig. 5). Particle diameters of 100-1000 μm were
observed after myopodin down-regulation showing that
reduced myopodin expression levels promote cell-cell
adhesion. These findings suggest that myopodin has a negative
effect on cell-cell contacts possibly by disturbing the inter-
action between the cell-cell adhesion complex and the actin
cytoskeleton.
Discussion
In this study we have demonstrated that siRNA-induced
down-regulation of the myopodin expression level reduces
invasion of human cancer cells in both collagen type I and
Matrigel. As such these findings corroborate earlier studies
showing that enhanced expression of myopodin in cells
elicits invasion (17). Furthermore, we provide evidence that
reduced invasion is linked to defects in cell motility and to
reinforcing E-cadherin mediated cell-cell contacts induced by
decreased myopodin levels. Taken together, this suggests a
potential role for myopodin as a tumor activator. Our data
further extend the concept that modulation of the expression
level of actin binding proteins affect cell motility and invasion.
For instance, overexpression of ·-actinin 4, an F-actin cross-
linking protein, induces the formation of filopodia and
increases cell motility (27). Moderate overexpression of green
fluorescent protein-tagged CapG (a ubiquitous nuclear-
cytoplasmic F-actin capping protein) in epithelial cells induces
invasion into collagen type I and in chick heart fragments.
However, CapG tagged with a nuclear export sequence,
preventing nuclear accumulation of the protein, is unable to
promote invasion, indicating that nuclear CapG is responsible
for the invasive phenotype (37). Overexpression of the F-actin
severing protein gelsolin promotes invasion of cells into
collagen type I and in chick heart fragments (18) whereas
down-regulation of gelsolin or CapG expression in various
types of cancer cells reduces invasion (38). As these proteins
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Figure 4. Down-regulation of myopodin offsets motility of PC-3 cells. A
wound healing assay was used to determine the effect of myopodin down-
regulation on the motility of PC-3 cells. Plotted curve of distance migrated
(y-axis) as a function of time (x-axis) are shown for PC-3 cells transfected
with the negative control siRNA duplex (solid line), with myopodin siRNA1
(dashed line) or myopodin siRNA2 (dashed-point line).
Figure 5. Reduced myopodin expression positively affects cell-cell contacts.
The effect of reduced myopodin expression using RNAi on the formation
of cell aggregates was investigated in a fast aggregation assay. Plotted
curves of relative volume distribution (y-axis) as a function of particle
diameter (x-axis) are shown after 30 min for PC-3 cells transfected with a
negative control siRNA duplex (solid line), PC-3 cells transfected with
myopodin siRNA1 (small-dashed line) or myopodin siRNA2 (large-dashed
line). The arrow indicates the peak position of the negative control siRNA-
treated cells after 0 min of aggregation.
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are directly involved in cell motility by virtue of their ability
to reorganize the actin cytoskeleton in migrating cells it seems
likely that the observed effect on cancer cell invasion is
linked to defects in motility.
Our findings diverge from earlier studies proposing a role
for myopodin as tumor suppressor (14-16,39). In those studies
however, a human myopodin variant was used that differs
from the human myopodin isoforms that we have identified
(13). Moreover, the myopodin variant has a different sub-
cellular localization than the three human myopodin isoforms
used in our studies (13). Whereas the 3 human myopodin
isoforms localize along actin filaments in the cytoplasm of
various cell lines, the myopodin variant used by others (16) is
detected both in the cytoplasm and in the nucleus. Several
lines of evidence support a model where the nuclear function
of myopodin is involved in the tumor suppressor activity of
myopodin and that cytoplasmic myopodin has a tumor
activator role (Fig. 6). For example, immunohistochemistry
on paired normal urothelium and bladder tumors showed
that in normal urothelium, myopodin is localized in both the
nucleus and the cytoplasm. In contrast, nuclear myopodin was
lost depending on the stage of bladder tumors (15). Tumors
with higher stage showed lower nuclear myopodin locali-
zation. Furthermore, large-scale analysis of a prostatic tissue
microarray led to the observation that cytoplasmic myopodin
was notably higher in cancer cells than in normal cells (39).
These observations propose that the cytoplasmic myopodin
pool gains importance during cancer progression. Moreover,
in vitro and in vivo functional studies proposing a tumor
suppressing function for myopodin were carried out with a
variant that localizes predominantly in the nucleus of these
cells (16,40). Interestingly, actin binding proteins residing
temporarily in the nucleus, including gelsolin, filamin A,
supervillin, cofilin and others, have been shown to act as
modulators of gene transcription controlled by nuclear
receptors (reviewed in ref. 41). Importantly, alignment of
all mouse and human myopodin isoforms known to date
shows that they contain the LXXLL signature, a motif
frequently encountered in co-regulators of nuclear receptors.
This ·-helical LXXLL motif, also called nuclear receptor
box, is believed to mediate the initial contact between nuclear
receptor and co-regulator to facilitate or impede transcription
activation (42-44). Loss of nuclear myopodin, as demon-
strated by several immunohistochemical studies, could thus
lead to changes in the gene transcription profile accompanying
and/or promoting cell transformation. Further experiments
are needed to investigate this hypothesis as well as the nature
of the putative nuclear receptors involved.
Several precedents have been documented showing
changes in the subcellular localization of actin binding proteins
during cancerogenesis. These include cofilin (45), ·-actinin 4
(26,46) and gelsolin (4). Whether the loss of nuclear myopodin
localization is due to changes in the nucleo-cytoplasmic
transport mechanism or the outcome of changes in myopodin
isoform expression remains to be determined.
Another explanation for the apparently contradictory
findings relating to the role of myopodin in cancer progression
may be that myopodin expression levels oscillate during
tumorigenesis. Such a biphasic pattern has also been suggested
for other actin binding proteins including gelsolin. Shieh et al
(47) described low gelsolin expression during early stages
of tumorigenesis followed by an increased expression in
invasive tumors, and concluded that different functions of
the protein are involved in different stages of carcinogenesis.
Further studies on the role of myopodin in tumorigenesis
taking the subcellular localization of the protein and the
different isoforms into consideration are therefore warranted.
Acknowledgements
This study was supported by the Concerted Actions Program
of Ghent University (GOA), the Fund for Scientific Research-
INTERNATIONAL JOURNAL OF ONCOLOGY  34:  1403-1409,  2009 1407
Figure 6. Model showing the relation between the subcellular localization of myopodin and its role in tumorigenesis. In normal cells, myopodin is localized in
both the cytoplasm and in the nucleus. Upon cell transformation, the nuclear-cytoplasmic equilibrium shifts in favor of the cytoplasmic localization. We
propose that the tumor suppressor role of myopodin is linked to its function in the nucleus (left), i.e. a putative function in gene transcription modulation. The
tumor promoter role of myopodin would be associated with its function in the cytoplasm, i.e. regulation of the organization of the actin cytoskeleton (right)
and cell motility. Myo, myopodin.
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